Fundamental Analysis of SALARIUS PHARMACEUTICALS INC(NASDAQ:SLRX) stock

Fundamental Rating

We assign a fundamental rating of 1 out of 10 to SLRX. SLRX was compared to 572 industry peers in the Biotechnology industry. Both the profitability and financial health of SLRX have multiple concerns. SLRX has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

SLRX had negative earnings in the past year.

In the past year SLRX has reported a negative cash flow from operations.

SLRX had negative earnings in each of the past 5 years.

In the past 5 years SLRX always reported negative operating cash flow.

1.2 Ratios

SLRX's Return On Assets of -129.40% is on the low side compared to the rest of the industry. SLRX is outperformed by 82.30% of its industry peers.

The Return On Equity of SLRX (-170.75%) is worse than 66.73% of its industry peers.

		Industry Rank	Sector Rank
ROA	-129.4%
ROE	-170.75%
ROIC	N/A

ROA(3y)-145.82%

ROA(5y)-103.7%

ROE(3y)-191.58%

ROE(5y)-135.06%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SLRX so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

SLRX has less shares outstanding than it did 1 year ago.

SLRX has more shares outstanding than it did 5 years ago.

SLRX has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -30.31, we must say that SLRX is in the distress zone and has some risk of bankruptcy.

With a Altman-Z score value of -30.31, SLRX is not doing good in the industry: 90.80% of the companies in the same industry are doing better.

SLRX has a Debt/Equity ratio of 0.11. This is a healthy value indicating a solid balance between debt and equity.

The Debt to Equity ratio of SLRX (0.11) is worse than 66.55% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.11
Debt/FCF	N/A
Altman-Z	-30.31

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 4.09 indicates that SLRX has no problem at all paying its short term obligations.

SLRX has a Current ratio (4.09) which is comparable to the rest of the industry.

A Quick Ratio of 4.09 indicates that SLRX has no problem at all paying its short term obligations.

SLRX has a Quick ratio (4.09) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Current Ratio	4.09
Quick Ratio	4.09

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for SLRX have decreased strongly by -14.71% in the last year.

EPS 1Y (TTM)-14.71%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%85.38%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

SLRX is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.22% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y21.55%

EPS Next 2Y-33.44%

EPS Next 3Y5.22%

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

SLRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SLRX. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-33.44%

EPS Next 3Y5.22%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

SLRX does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

SALARIUS PHARMACEUTICALS INC

NASDAQ:SLRX (1/14/2025, 8:05:43 PM)

Premarket: 2.75 +0.11 (+4.17%)

2.64

-1.03 (-28.07%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-14 2024-11-14/amc

Earnings (Next)N/A N/A

Inst Owners1.81%

Inst Owner Change0%

Ins Owners2.52%

Ins Owner Change0%

Market Cap3.80M

Analysts43.33

Price Target26.52 (904.55%)

Short Float %2.22%

Short Ratio0.01

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)N/A

DP0%

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	1.3
P/tB	1.3
EV/EBITDA	N/A

EPS(TTM)-8.19

EYN/A

EPS(NY)-9.35

Fwd EYN/A

FCF(TTM)-3.68

FCFYN/A

OCF(TTM)-3.68

OCFYN/A

SpS0

BVpS2.03

TBVpS2.03

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-129.4%
ROE	-170.75%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-145.82%

ROA(5y)-103.7%

ROE(3y)-191.58%

ROE(5y)-135.06%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score5

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0.11
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	4.09
Quick Ratio	4.09
Altman-Z	-30.31

F-Score5

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-14.71%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%85.38%

EPS Next Y21.55%

EPS Next 2Y-33.44%

EPS Next 3Y5.22%

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y71.65%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y66.03%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y66.03%

OCF growth 3YN/A

OCF growth 5YN/A

SALARIUS PHARMACEUTICALS INC (SLRX)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens